Customised Services in Preclinical Inflammation

Publicerad 2020-02-11

NeutroCure kick-off meeting

Last week, we successfully kicked off the Horizon 2020 funded FETOPEN program NeutroCure (agreement No 861878).

The consortium, with partners from Friedrich-Alexander-Universitaet Erlangen Nuernberg and Universitatsklinikum Erlangen (Germany), University of Surrey (UK), Lvivskyi Nationalnyi Medychinyi Universytet Imeni Danyla Halytskoho (Ukraine), Centro Nacional de Investigiciones Cardiovasculares Carlos III (F.S.P) (Spain) and Institute Gustave Roussy (France) meet in Erlangen for a day of discussions on neutrofils and oxidation in regulation of the immune system. Redoxis look forward to the next five years of collaboration and the research that will be the result of this. We aim to identify candidate ROS amplifier drugs and prodrugs to treat pathogenic conditions arising due to insufficient production of reactive oxygen species (ROS), including autoimmune disease, cancer and bone marrow ablation. We will advance these drugs from lab bench to pre-clinical validation studies obtaining new drugs with strong therapeutic value.

The Redoxis team at a dinner table